Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetanus toxoid + diphtheria toxoid + pertussis vaccine (acellular, component) + influenza vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Boostrix + Fluarix refers to the concomitant administration of two vaccines developed by GSK: Boostrix, a Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis) vaccine, and Fluarix, an inactivated seasonal influenza vaccine. Boostrix is indicated for active booster immunization against tetanus, diphtheria, and pertussis in individuals aged 10 years and older. Fluarix (specifically the quadrivalent formulation) is indicated for active immunization against influenza A and B viruses. Clinical studies have demonstrated that the co-administration of these two vaccines at separate injection sites is safe and does not interfere with the immune response to either vaccine, providing a convenient option for adolescent and adult immunization schedules to improve coverage for these five pathogens.
- Other names
- Boostrix + FluarixTdap + Influenza vaccineBoostrix and Fluarix co-administration
02
Targets
HA (Hemagglutinin)FHA (Filamentous hemagglutinin)PRN (Pertactin)Diphtheria toxin
Beyond the preview
Go deeper on tetanus toxoid + diphtheria toxoid + pertussis vaccine (acellular, component) + influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetanus toxoid + diphtheria toxoid + pertussis vaccine (acellular, component) + influenza vaccine.